Half-Dose Radiopharmaceutical in Wide Beam Reconstruction
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is recruiting patients already scheduled for a single photon emission computed
tomography myocardial perfusion imaging (SPECT-MPI) test. SPECT-MPI is a nuclear imaging
technique that uses a radioactive substance, or radiotracer, and special equipment to create
three-dimensional (3D) images of the heart. Radiotracer is a radioactive dye that will make
the structures of the heart visible and is routinely used to view blood flow in the heart,
scan for damaged heart tissue, or assess heart function.
For a routine SPECT-MPI test, the radiotracer is given in one dose at the beginning of the
test, followed by taking resting images of the heart. For this study, researchers would like
to administer half of the radiotracer, obtain resting images, administer the remainder of the
radiotracer and obtain a second set of resting images. Participants will receive the same
amount of radioactive material that would normally be given for this test; however, it will
be administered in two half-doses. Participation in this study will add about 30 minutes to
the time it takes to complete the routine test. The investigators expect to enroll about 160
subjects in this study at Northwestern.